MicroRNA as a marker for kidney cancer
A recent study has provided evidence that a group of [...]
SMC approves lenvatinib plus everolimus combination for second-line treatment of advanced kidney cancer
We are delighted to announce that the Scottish Medicines Consortium (SMC), [...]
Avelumab as a first- or second-line treatment for metastatic kidney cancer
A recent study looked at the efficacy and safety of [...]
Comparison of first-line immunotherapy combinations for advanced kidney cancer
In this paper, three clinical trials with immunotherapy combinations for [...]
Kidney cancer surgery in older patients
The RESURGE project retrospectively analysed data from three published studies [...]
Lenvatinib plus pembrolizumab combination shows promise in metastatic kidney cancer
Interim results from an ongoing clinical trial of lenvatinib and [...]
Sunitinib and pazopanib for non-clear cell and sarcomatoid kidney cancer
Non-clear cell renal cell carcinoma (RCC) and sarcomatoid renal cell [...]
Negative effect on survival of kidney cancer patients of immediate sunitinib dose interruption
A recent study looked at the impact of stopping sunitinib [...]
Potential new treatments for kidney cancer discussed at 2019 Kidney Cancer Research Summit
In this interview from the 2019 Kidney Cancer Research Summit [...]
Treatment with stereotactic body radiotherapy plus TKIs or immunotherapy is safe and may improve survival of metastatic kidney cancer patients
Two small studies looked at the addition of a type [...]
